Ignite Creation Date:
2025-12-25 @ 1:26 AM
Ignite Modification Date:
2026-01-02 @ 9:33 PM
Study NCT ID:
NCT00952393
Status:
COMPLETED
Last Update Posted:
2016-02-05
First Post:
2009-08-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Nicotinic Receptors and Schizophrenia
Sponsor:
VA Office of Research and Development
Organization:
Study Overview
Official Title:
Nicotinic Receptors and Schizophrenia
Status:
COMPLETED
Status Verified Date:
2016-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study determines if a new preparation of a drug designed to treat schizophrenia is more slowly released into the body.
Detailed Description:
3-2,4 dimethoxybenzylidene will be compounded with a methyallose compound in doses of 150 and 300 mg. The capsules will be administered singly and eventually bid to determine if sustained blood levels comparable to steady state blood levels seen in previous studies can be determined. Safety and EEG effects will be measured.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: